Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Biomira and Merck announce fast track status for liposome vaccine

Biomira and Merck KGaA have announced that the U.S. Food & Drug Administration (FDA) has granted Fast Track status to the investigation of BLP25 Liposome Vaccine (L-BLP25) for its proposed use in the treatment of non-small cell lung cancer (NSCLC).

29 Sep 2004

Trial shows which brain cancer patients benefit from temozolomide

An international team of scientists and cancer specialists has identified which patients with the deadly form of brain tumours called glioblastomas are likely to live longer if they are treated with temozolomide, and which patients are likely to get only marginal, if any, benefit.

28 Sep 2004

Researchers reveal potential new role for Glivec/Imatinib

Imatinib – or Glivec as it also known – looks as if it may become an effective treatment for yet another type of cancer.

28 Sep 2004

Arsenic trioxide - invented as a treatment for a rare type of leukaemia

Arsenic trioxide – a highly poisonous substance best known as an effective weed killer or pesticide and notorious for being a favourite ‘weapon’ of choice in murder mystery novels, is being re-invented as a treatment for a rare type of leukaemia.

28 Sep 2004

Group therapy does not improve survival in early-stage breast cancer patients

A new study shows that cognitive-existential group therapy (CEGT), a psychosocial intervention designed to improve the mood and attitude of patients with breast cancer, does not improve survival of women with early-stage disease.

27 Sep 2004

Discovery of key molecular step which allows cancer cells to move to different parts of the body

Researchers at The University of Texas M. D. Anderson Cancer Center have figured out a key molecular step by which a cancer cell can unhook itself from the mesh weave of other cancer cells in a tumor, and move away to a different part of the body - the process, known as metastasis, that makes cancer so dangerous.

27 Sep 2004

Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder

AstraZeneca has announced important new data at the 4th European Stanley Foundation Conference on Bipolar Disorder, which show Seroquel is significantly more effective than placebo in treating patients with rapid-cycling bipolar disorder and is also well-tolerated in this difficult to treat patient population.

26 Sep 2004

HER-2 cell surface receptors tun on genes associated with carcinogenesis

Researchers at The University of Texas M. D. Anderson Cancer Center now have evidence that receptors found on tumors that were believed to function only on the surface of cells can actually switch on genes inside a cell's nucleus, thus promoting cancer development in two distinct ways.

21 Sep 2004

Half of patients with aggressive non-Hodgkin's lymphoma fail to receive the recommended dose and schedule of chemotherapy

Approximately half of patients with aggressive non-Hodgkin's lymphoma (NHL) fail to receive the recommended dose and schedule of chemotherapy, reducing their chances for remission or cure.

20 Sep 2004

Breast reconstruction at the time of mastectomy does not delay post-operative chemotherapy for women with breast cancer

“The findings weren’t a surprise to us, but we wanted to document the safety of immediate breast reconstruction so that surgeons in other settings can have the same confidence in the approach,” Bold said.

20 Sep 2004

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

Cytogen Corporation today announced the presentation of new data relating to its lead therapeutic product Quadramet (samarium Sm-153 lexidronam injection) during the 36th Congress of the International Society of Pediatric Oncology (SIOP).

20 Sep 2004

Isis Pharmaceuticals licenses second anti-cancer drug candidate to Lilly

Isis Pharmaceuticals announced today that Eli Lilly and Company licensed LY2275796, a second-generation antisense anti-cancer drug candidate for clinical development.

20 Sep 2004

Tarceva plus Gemcitabine improves survival compared to Gemcitabine alone

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche announced today that results from a randomized Phase III clinical study of the investigational drug Tarceva (erlotinib HCl), in combination with gemcitabine chemotherapy met its primary endpoint of improving survival.

20 Sep 2004

Less radiation in a more tailored manner best for uterine cancer

Less radiation, delivered in a more tailored manner, is very effective and should be preferred over longer-term conventional radiation therapy in treating one of the most virulent forms of uterine cancer

20 Sep 2004

New method targeting hypermethylation detects ovarian cancer in the blood

Fox Chase Cancer Center researchers have found a new way to detect ovarian cancer in the blood. Reported in the Sept. 15, 2004, issue of Cancer Research, the new method targets hypermethylation--one mechanism used by cancer cells to turn off genes that protect against tumor development.

16 Sep 2004

ChemGenex discovers five new depression genes

ChemGenex Pharmaceuticals has announced that it has filed for patent protection for a further five novel depression-associated gene targets discovered by its depression and anxiety research group.

16 Sep 2004

Drug combo may have a greater impact on cancer development

Cancer researchers have long suggested that new targeted drugs may work best when paired with other therapies. In a new study published today in Cancer Research, scientists have taken some of the first steps to demonstrate this synergy in mouse and cell line models.

16 Sep 2004

BNCT treatment has had an excellent response in a patient with head and neck cancer

A Finnish research group has been the first in the world to publish an article in which BNCT treatment has had an excellent response in a patient with head and neck cancer for whom there was no other treatment available.

14 Sep 2004

Schering-Plough and Bayer form strategic alliance

Schering-Plough Corporation has announced that it has entered into a strategic agreement with Bayer designed to maximize the companies' pharmaceutical resources while maintaining each company's own strategic interests.

13 Sep 2004

Researchers have discovered a possible way to distinguish lethal from localized prostate cancers

If future studies show their test -- measuring the level of activity of a signaling pathway called Hedgehog -- can predict which prostate cancers will spread, the results could revolutionize decision making processes for prostate cancer patients, the researchers say.

13 Sep 2004